Drug Profile
Research programme: diabetes therapy - Protemix
Alternative Names: PX 811014; PX 811016Latest Information Update: 27 Jun 2013
Price :
$50
*
At a glance
- Originator Protemix Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Jun 2010 Discontinued - Preclinical for Type-2 diabetes mellitus in New Zealand (unspecified route)
- 03 May 2005 Preclinical trials in Type-2 diabetes mellitus in New Zealand (unspecified route)